XSHE
300952
Market cap581mUSD
Oct 09, Last price
15.88CNY
1D
-1.37%
1Q
-16.11%
IPO
-67.46%
Name
Jiangsu Hanvo Safety Product Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Hanvo Safety Product Co., Ltd. engages in the research and development, production, and sale of special safety and health protection products in China. The company offers special safety and health protection products, including gloves, clothing, shoes, and hats; new graphene ultra-fiber materials; protective equipment for medical staff; and medical and daily masks, as well as technical development, consultation, exchange, and other technical services; and technology transfer and promotion services. It is also involved in the wholesale and retail of protective equipment for medical staff. The company exports its products to approximately 50 countries and regions, including Europe, the United States, Japan, and internationally. Jiangsu Hanvo Safety Product Co., Ltd. was founded in 2004 and is based in Nantong, China.
Key people
Xiaoning Zhu
Chief Financial Officer · since 2025
Peng Wang
Chief Marketing Officer, Deputy General Manager, Director · since 2025
Xiaodong Ding
Deputy General Manager · since 2025
Yun Lu
Deputy General Manager · since 2024
Shuangcheng Wang
Deputy General Manager · since 2022
Jingjing Wang
Deputy General Manager · since 2024
Wufen Zhang
Deputy General Manager, Secretary of the Board, Director · since 2021
Jiajia Fan
Director · since 2025
Xueling Shi
Staff Elected Director · since 2025
Xianhua Wang
Chairman of the Board, General Manager · since 2017
Haixia Yao
Director · since 2017
Fei Chen
Independent Director · since 2025
Minmin Pu
Independent Director · since 2024
Xiuting Yuan
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||